 |
|
VIGNETTES
Classic Mediterranean Kaposi’s Sarcoma Regression With Sirolimus Treatment
Emmanuella Guenova, MD;
Gisela Metzler, MD;
Wolfram Hoetzenecker, MD, PhD;
Mark Berneburg, MD;
Martin Rocken, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Replacement of mycophenolate mofetil, cyclosporine, or tacrolimus by sirolimus results in regression of Kaposi's sarcoma (KS) in organ transplant recipients.1-3 In these patients, clearance from KS might result either from reduced immunosuppression or from the direct antiangiogenic effects of sirolimus.
Report of a Case
Herein we describe a 62-year-old man with disseminated Mediterranean KS that regressed almost completely during sirolimus therapy at a blood concentration of 6 ng/mL. The heterosexual, immunocompetent patient tested negative for both human immunodeficiency virus 1 and human immunodeficiency virus 2. However, he had 17 disseminated KS lesions that continuously erupted after excision of 2 single KS lesions that tested positive for human herpesvirus 8 and the D2-40 antibody (which is raised against M2A, an oncofetal antigen, and has been used as a marker for lymphatic endothelium). Owing to the large number of KS . . . [Full Text of this Article]
Comment
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Kaposi’s Sarcoma Resolves After Sirolimus Therapy in a Patient With Pemphigus Vulgaris
Sarika Saggar, Joshua A. Zeichner, Tamu T. Brown, Robert G. Phelps, and Steven R. Cohen
Arch Dermatol. 2008;144(5):654-657.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Dual Inhibition of PI3K{alpha} and mTOR as an Alternative Treatment for Kaposi's Sarcoma
Chaisuparat et al.
Cancer Res. 2008;68:8361-8368.
ABSTRACT
| FULL TEXT
|
